Activating mutations in the EGFR gene are present in approximately 10%–35% of non-small-cell lung cancer (NSCLC) patients, and in-frame deletion in exon 19 (LREA deletions) and substitutions in exon 21 (L858R) account for more than 85% of known EGFR alterations (Westover et al., 2018; Kobayashi and Mitsudomi, 2016). Here, EGFR is linked to non-small cell lung carcinoma.